Literature DB >> 23740920

Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.

Mirte Scherpenisse1, Rutger M Schepp, Madelief Mollers, Sofie H Mooij, Chris J L M Meijer, Guy A M Berbers, Fiona R M van der Klis.   

Abstract

We compared the measurement of human papillomavirus (HPV)-specific serum antibody levels with the virus-like-particle multiplex immunoassay (VLP-MIA), competitive Luminex immunoassay (cLIA), and glutathione S-transferase (GST) L1-based MIA. Using a large panel of serum samples, these assays showed mutually good correlations for both naturally induced and vaccine-derived HPV-specific antibody levels. However, an adaptation of the GST L1-based MIA resulted in an improved correlation with both cLIA and VLP-MIA.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23740920      PMCID： PMC3754499          DOI： 10.1128/CVI.00153-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  16 in total

1.  Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae.

Authors:  J L Rossi; L Gissmann; K Jansen; M Müller
Journal:  Hum Gene Ther       Date:  2000-05-20       Impact factor: 5.695

2.  Suppression of non-specific binding in serological Luminex assays.

Authors:  Tim Waterboer; Peter Sehr; Michael Pawlita
Journal:  J Immunol Methods       Date:  2005-12-19       Impact factor: 2.303

3.  Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.

Authors:  M Mollers; M Scherpenisse; F R M van der Klis; A J King; T G J van Rossum; E M van Logchem; M C Feltkamp; C J L M Meijer; P J F Snijders; H J Boot; H E de Melker
Journal:  Cancer Epidemiol       Date:  2012-08-17       Impact factor: 2.984

4.  Stability over time of serum antibody levels to human papillomavirus type 16.

Authors:  V af Geijersstam; M Kibur; Z Wang; P Koskela; E Pukkala; J Schiller; M Lehtinen; J Dillner
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

6.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.

Authors:  Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

7.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

8.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

9.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

10.  Prevalence of human papillomavirus antibodies in young female subjects in England.

Authors:  M Jit; A Vyse; R Borrow; R Pebody; K Soldan; E Miller
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640
View more
  8 in total

Review 1.  EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.

Authors:  Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi
Journal:  Int J Cancer       Date:  2014-07-26       Impact factor: 7.396

Review 2.  Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology.

Authors:  Joan Campbell-Tofte; Aristidis Vrahatis; Knud Josefsen; Jesper Mehlsen; Kaj Winther
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

3.  Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.

Authors:  G Panicker; I Rajbhandari; B M Gurbaxani; T D Querec; E R Unger
Journal:  J Immunol Methods       Date:  2014-12-30       Impact factor: 2.303

4.  Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

Authors:  Ping Du; Sarah Brendle; Janice Milici; Fabian Camacho; John Zurlo; Neil Christensen; Craig Meyers
Journal:  J AIDS Clin Res       Date:  2015-03

5.  Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study.

Authors:  Christine M Pierce Campbell; Raphael P Viscidi; B Nelson Torres; Hui-Yi Lin; William Fulp; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Aimée R Kreimer; Anna R Giuliano
Journal:  J Infect Dis       Date:  2016-02-29       Impact factor: 5.226

6.  HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.

Authors:  Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano
Journal:  Papillomavirus Res       Date:  2017-02-16

7.  Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Authors:  Hilary A Robbins; Yan Li; Carolina Porras; Michael Pawlita; Arpita Ghosh; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy J Kemp; Paula Gonzalez; John Schiller; Douglas Lowy; Mark Esser; Katie Matys; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Ligia A Pinto; Allan Hildesheim; Tim Waterboer; Mahboobeh Safaeian
Journal:  BMC Infect Dis       Date:  2014-03-03       Impact factor: 3.090

Review 8.  Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge.

Authors:  J Hoes; H Pasmans; T M Schurink-van 't Klooster; F R M van der Klis; R Donken; J Berkhof; H E de Melker
Journal:  Hum Vaccin Immunother       Date:  2021-05-25       Impact factor: 3.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.